Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting pancreatic cancer glutamine dependency confers vulnerability to GPX4-dependent ferroptosis

28 Jan 2025

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) relies heavily on glutamine (Gln) utilization to meet its metabolic and biosynthetic needs. How epigenetic regulators contribute to the metabolic flexibility and PDAC's response and adaptation to Gln scarcity in the tumor milieu remains largely unknown. Here, we elucidate that prolonged Gln restriction or treatment with the Gln antagonist, 6-diazo-5-oxo-L-norleucine (DON),...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Ferroptosis and cancer prognosis
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39879992
DOI: 10.1016/j.xcrm.2025.101928

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting pancreatic cancer glutamine dependency confers vulnerability to GPX4-dependent ferroptosisPMID 39879992Read ↗

Pyruvate Kinase Activity Regulates Cystine Starvation Induced Ferroptosis through Malic Enzyme 1 in Pancreatic Cancer CellsSemantic proximity Read ↗

Adaptation of pancreatic cancer cells to nutrient deprivation is reversible and requires glutamine synthetase stabilization by mTORC1Semantic proximity Read ↗

Glutamine-restricted diets restore sensitivity to KRASG12D inhibitor through the reversal of ANXA1 mediated metabolic reprogramming.Semantic proximity Read ↗

SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine-Resistance in Pancreatic CancerSemantic proximity Read ↗

Compensatory metabolic networks in pancreatic cancers upon perturbation of glutamine metabolismSemantic proximity Read ↗

Loss of heterozygosity for KrasG12D promotes REDD1-dependent, non-canonical glutamine metabolism in pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

Supraphysiological glutamine as a means of depleting intracellular amino acids to enhance pancreatic cancer chemosensitivitySemantic proximity Read ↗

“Induction of pancreatic tumor-selective ferroptosis through modulation of cystine import”Semantic proximity Read ↗

Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers.Semantic proximity Read ↗

Glutamine Transporter SLC1A5 Regulates Ionizing Radiation‐Derived Oxidative Damage and FerroptosisSemantic proximity Read ↗

Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapySemantic proximity Read ↗

Netrin G1 promotes pancreatic tumorigenesis through cancer associated fibroblast driven nutritional support and immunosuppressionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.